Cargando…

Correlates of plasma and platelet tissue factor pathway inhibitor, factor V, and Protein S

ESSENTIALS: Tissue Factor Pathway Inhibitor, Protein S, and Factor V circulate in plasma and platelet pools. These proteins were measured in plasma and platelets from 435 healthy subjects and correlated. Plasma and platelet pools differ in their demographic correlates and alterations by estrogen. Pl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ellery, Paul E. R., Hilden, Ida, Sejling, Ken, Loftager, Mette, Martinez, Nicholas D., Maroney, Susan A., Mast, Alan E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles: Thrombosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771435/ https://www.ncbi.nlm.nih.gov/pubmed/29354797 http://dx.doi.org/10.1002/rth2.12058

Ejemplares similares

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice
por: Østergaard, Henrik, et al.
Publicado: (2021)

Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI
por: Li, Chan, et al.
Publicado: (2019)

Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200
por: Zhu, Shuhao, et al.
Publicado: (2020)

Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa
por: Heitmeier, Stefan, et al.
Publicado: (2022)

The Btk inhibitor AB‐95‐LH34 potently inhibits atherosclerotic plaque–induced thrombus formation and platelet procoagulant activity
por: Smith, Christopher W., et al.
Publicado: (2022)

Elevated plasma levels of plasminogen activator inhibitor‐1 are associated with risk of future incident venous thromboembolism
por: Frischmuth, Tobias, et al.
Publicado: (2022)

Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits
por: Wong, Pancras C., et al.
Publicado: (2021)

Factor VIII as a potential player in cancer pathophysiology
por: Walker, Gillian E., et al.
Publicado: (2022)

Oxidative stress mediated platelet activation in patients with congenital analbuminemia: Effect of albumin infusion
por: Baratta, Francesco, et al.
Publicado: (2021)

The roles of factor Va and protein S in formation of the activated protein C/protein S/factor Va inactivation complex
por: Gierula, Magdalena, et al.
Publicado: (2019)

Effect of antiplatelet agents and tyrosine kinase inhibitors on oxLDL-mediated procoagulant platelet activity
por: Zheng, Tony J., et al.
Publicado: (2022)

Targeted SERPIN (TaSER): A dual‐action antithrombotic agent that targets platelets for SERPIN delivery
por: Sanrattana, Wariya, et al.
Publicado: (2021)

ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia
por: Karnes, Jason H., et al.
Publicado: (2022)

Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery—Systematic review and meta‐analysis
por: Presume, João, et al.
Publicado: (2022)

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban
por: Bosch, Floris T. M., et al.
Publicado: (2021)

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men
por: Nowotny, Bettina, et al.
Publicado: (2022)

Procoagulant factor levels and risk of venous thrombosis in the elderly
por: Wang, Huijie, et al.
Publicado: (2020)

Growth differentiation factor‐15 for prediction of bleeding in cancer patients
por: Mulder, Frits I., et al.
Publicado: (2021)

Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen
por: Bar Barroeta, Awital, et al.
Publicado: (2022)

Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII
por: Demers, Melanie, et al.
Publicado: (2022)

Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo
por: Perzborn, E, et al.
Publicado: (2014)

The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer
por: Zhu, Shuhao, et al.
Publicado: (2020)

Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel
por: Gasecka, Aleksandra, et al.
Publicado: (2020)

Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein
por: Greinacher, Andreas, et al.
Publicado: (2021)

Identification of cysteine thiol‐based linkages in ADAMTS13 in support of a non‐proteolytic regulation of von Willebrand factor
por: Rottensteiner, Hanspeter, et al.
Publicado: (2019)

Associations of coagulation factor X and XI with incident acute coronary syndrome and stroke: A nested case‐control study
por: Chen, Huiting, et al.
Publicado: (2021)

Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration
por: Dhami, Sukhraj Pal Singh, et al.
Publicado: (2022)

Paving the way for establishing a reference measurement system for standardization of plasma prothrombin time: Harmonizing the manual tilt tube method
por: van den Besselaar, Antonius M. H. P., et al.
Publicado: (2020)

Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a)
por: Pasternack, Ralf, et al.
Publicado: (2019)

The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study
por: Overvad, Thure F., et al.
Publicado: (2022)

Anti-HK antibody inhibits the plasma contact system by blocking prekallikrein and factor XI activation in vivo
por: Chen, Zu-Lin, et al.
Publicado: (2022)

Novel mechanism regulating tissue factor activity
por: Nieuwland, Rienk
Publicado: (2021)

Platelet-targeted thrombolysis for treatment of acute ischemic stroke
por: Palazzolo, Jason S., et al.
Publicado: (2022)

Cleavage of talin by calpain promotes platelet-mediated fibrin clot contraction
por: Fong, Karen P., et al.
Publicado: (2021)

INR and vitamin K–dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma
por: Hood, Christopher, et al.
Publicado: (2022)

Venous thrombosis risk during and after medical and surgical hospitalizations: The medical inpatient thrombosis and hemostasis (MITH) study
por: Jordan Bruno, Ximena, et al.
Publicado: (2022)

Clot‐targeted magnetic hyperthermia permeabilizes blood clots to make them more susceptible to thrombolysis
por: Cabrera, David, et al.
Publicado: (2022)

Structure of coagulation factor VIII bound to a patient-derived anti–C1 domain antibody inhibitor
por: Childers, Kenneth C., et al.
Publicado: (2023)

Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
por: Berkowitz, Scott D., et al.
Publicado: (2022)

Biomarkers for Thrombosis in COVID-19: A Role for High Sensitivity Troponin-I and Immature Platelet Fraction?
por: Ashraf, Bilal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_te346i5se0cru14c1u4hg98ug8